Navco Pharmaceuticals Inc.
NAV.V
TSX
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -60.56% | -38.35% | 98.77% | 457.67% | -- |
| Depreciation & Amortization | 43.96% | 67.49% | 97.44% | 36.42% | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -57.74% | -35.17% | 98.63% | 409.90% | -- |
| Operating Income | 57.74% | 35.17% | -99.98% | -440.93% | -- |
| Income Before Tax | 37.75% | 20.63% | 113.84% | -604.47% | -- |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 37.75% | 20.63% | 113.84% | -604.47% | -- |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 37.75% | 20.63% | 113.84% | -604.47% | -- |
| EBIT | 57.74% | 35.17% | -99.98% | -440.93% | -- |
| EBITDA | 61.95% | 38.89% | -100.66% | -493.50% | -- |
| EPS Basic | 56.56% | 43.29% | 117.12% | -249.26% | -- |
| Normalized Basic EPS | 69.50% | 52.11% | -49.12% | -155.81% | -- |
| EPS Diluted | 56.56% | 43.29% | 117.12% | -249.26% | -- |
| Normalized Diluted EPS | 69.50% | 52.11% | -49.12% | -155.81% | -- |
| Average Basic Shares Outstanding | 64.75% | 77.28% | 60.82% | 89.56% | -- |
| Average Diluted Shares Outstanding | 64.75% | 77.28% | 60.82% | 89.56% | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |